Using PCR amplification followed by confirmation with Bst U I restriction enzyme digestion, the p53 Pro sequence was determined in tissues from 88 normal cervices, in 184 cervical swabs with mildly abnormal Pap smear, in 50 squamous cell cervical carcinoma specimens, and in 30 cervical adenocarcinoma samples. The frequencies for homozygous proline (Pro-72), homozygous arginine (Arg-72), and heterozygous proline/arginine (Pro/Arg-72) were 23% (n = 20), 28% (n = 25), and 49% (n = 43), respectively, in normal cervices; 24% (n = 45), 28% (n = 51), and 48% (n = 88), respectively, in samples with mild dyskaryotic changes in Pap smears; 26% (n = 13), 28% (n = 14), and 46% (n = 23), respectively, in squamous cell carcinomas, and 33.3% (n = 26), 46.2% (n = 36), and 20.5% (n = 16), respectively, in adenocarcinomas. In the present study, we have found that p53 polymorphism may have a role in the development of adenocarcinoma but not squamous cell carcinoma. The arginine-encoding allele may thus be an important factor affecting host susceptibility to the development of adenocarcinoma.

Keywords:
Cervical cancer, p53 Polymorphism, Adenocarcinoma
This content is only available via PDF.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.